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PREMISE: How genetic variation within a species affects phytochemical composition is
a fundamental question in botany. The ratio of two specialized metabolites in Cannabis
sativa, tetrahydrocannabinol (THC) and cannabidiol (CBD), can be grouped into
three main classes (THC-type, CBD-type, and intermediate type). We tested a genetic
model associating these three groups with functional and nonfunctional alleles of the
cannabidiolic acid synthase gene (CBDAS).
METHODS: We characterized cannabinoid content and assayed CBDAS genotypes of >300
feral C. sativa plants in Minnesota, United States. We performed a test cross to assess CBDAS
inheritance. Twenty clinical cultivars obtained blindly from the National Institute on Drug
Abuse and 12 Canadian-certified grain cultivars were also examined.
RESULTS: Frequencies of CBD-type, intermediate-type, and THC-type feral plants were 0.88,
0.11, and 0.01, respectively. Although total cannabinoid content varied substantially, the
three groupings were perfectly correlated with CBDAS genotypes. Genotype frequencies
observed in the test cross were consistent with codominant Mendelian inheritance of the
THC:CBD ratio. Despite significant mean differences in total cannabinoid content, CBDAS
genotypes blindly predicted the THC:CBD ratio among clinical cultivars, and the same was
true for industrial grain cultivars when plants exhibited >0.5% total cannabinoid content.
CONCLUSIONS: Our results extend the generality of the inheritance model for THC:CBD
to diverse C. sativa accessions and demonstrate that CBDAS genotyping can predict the
ratio in a variety of practical applications. Cannabinoid profiles and associated CBDAS
segregation patterns suggest that feral C. sativa populations are potentially valuable
experimental systems and sources of germplasm.
KEY WORDS

Cannabaceae; CBDA synthase; chemotype; genetic markers; hemp;

marijuana.

Natural genetic variation affects the composition of phytochemicals
in plants and can be of great economic importance. With a record
of use by humans as food, fiber, and medicine spanning thousands
of years (Faeti et al., 1996), recent decades of prohibition, and a rapidly changing regulatory context, Cannabis sativa L. (Cannabaceae)
was until recently among the least studied agricultural crops (Small,
2016). Prominent among the traits of C. sativa are cannabinoids, a
unique class of specialized metabolites synthesized and stored in
glandular trichomes that are located on the floral bracts of pistillate inflorescences (Livingston et al., 2020; Fig. 1A–C). The ratio
of the two most abundant cannabinoids, tetrahydrocannabinolic
acid (THCA) and cannabidiolic acid (CBDA), hereafter THC and

CBD, is represented by three main classes: THC-type plants with
THC:CBD ≥ 10, intermediate-type plants with THC:CBD ≈ 1, and
CBD-type plants with THC:CBD ≤ 0.1 (de Meijer et al., 2003). Some
authors have referred to these chemotype (chemical phenotype)
classes as Type I, Type II, and Type III (Small, 2016). Here we introduce for clarity a more descriptive classification of THC-type,
intermediate-type, and CBD-type plants. Descriptive terms also
avoid confusion associated with recent statutory definitions of C.
sativa that vary widely among political jurisdictions (e.g., “industrial hemp” and “medical marijuana”). Our findings suggest that
patterns of cannabinoid inheritance render some of these popular
definitions inaccurate at least from a botanical perspective.
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FIGURE 1. Cannabinoid biosynthesis occurs in glandular trichomes borne primarily on pistillate inflorescences composed of leaves, bracts, and florets. (A) Pistillate inflorescence with receptive, white stigmas before pollination. Scale bar = 1 cm. Photo credit: George Weiblen. (B) Scanning electron
micrograph of an immature pistillate floret enclosed by a pair of imbricate bracts (br1 and br2) bearing multicellular hairs. Scale bar = 0.1 mm. Photo
credit: David Marks. (C) Scanning electron micrograph of stalked glandular trichomes (gt), sessile glands (sg), and cystoliths (cy). Cystoliths are pointed
hairs containing calcium carbonate crystals. Scale bar = 100 µm. Photo credit: David Marks. (D) Biosynthesis of major cannabinoid compounds. CBDA
and THCA are produced enzymatically from a common CBGA precursor by different enzymes. Both compounds may be decarboxylated to pharmacologically active neutral forms CBD and THC, respectively.

Synthesis of CBD and THC involves a common precursor, cannabigerolic acid or CBGA (Taura et al., 1995) (Fellermeier et al.,
2001), and the inheritance of major chemotypes is consistent with
single-locus Mendelian codominance (de Meijer et al., 2003). de
Meijer et al. (2003) proposed a model in which alternate alleles determine THC-type and CBD-type in the respective homozygous
plants, whereas heterozygous plants have the intermediate-type.
However, DNA sequencing uncovered the presence of separate but
tightly linked loci for the THCA synthase (THCAS) and CBDA synthase genes (CBDAS), respectively (van Bakel et al., 2011; Onofri
et al., 2015; Weiblen et al., 2015; Grassa et al., 2018 [Preprint];
Laverty et al., 2019). Given the impact of the THC:CBD ratio on
various licit and illicit uses, developing molecular markers to more
completely diagnose its genetic basis can aid efforts to regulate and
improve C. sativa.
Predicting the THC:CBD ratio from a PCR-based assay was
first claimed by Pacifico et al. (2006), but primers were not made
available. Rotherham and Harbison (2011) reported a set of
single nucleotide polymorphism (SNP) markers based on differences between “drug-type” and “fiber-type” THCAS (Kojoma
et al., 2006), but the latter THCAS sequence was reclassified by
Laverty et al. (2019) as cannabichromenic acid synthase (CBCAS).
These SNP markers and others derived from THCAS sequence
(Staginnus et al., 2014) can distinguish THC-type and CBD-type
plants, but they fail to differentiate THC-type from intermediate-type plants (Toth et al., 2020).

In an F2 mapping population derived from a cross of THCtype and CBD-type, we reported the correspondence of three
THC:CBD ratio classes with different combinations of CBDAS
alleles, noting a four-base, frame shift deletion near the 5′ end of
the CBDAS sequence in THC-type plants (Weiblen et al., 2015).
From this observation, we hypothesized a model of chemotype
inheritance in which plants that are homozygous for nonfunctional and functional CBDAS have THC-type and CBD-type cannabinoid ratios. Plants that are heterozygous at the CBDAS locus
have the intermediate type. The opportunity to test the validity
of the model and its utility for predictive genotyping has only
recently emerged with greater access to diverse populations of C.
sativa (Toth et al., 2020).
We applied a research protocol approved by the U. S. Drug
Enforcement Administration (DEA) to study feral C. sativa in
the Minnesota River Valley (Fig. 2), aiming to test the CBDAS
inheritance model that emerged from our previous mapping
study. We confirmed that cannabinoid profiles and CBDAS genotypes of feral individuals are congruent with the model, as
was the segregation of genotypes and phenotypes in a feral test
cross. Additionally, we tested samples obtained blindly from the
National Institute on Drug Abuse (NIDA) to validate the model
by predicting the cannabinoid ratios of 20 clinical cultivars.
Lastly, we demonstrated the utility of the CBDAS assay for predicting THC:CBD ratios in regulated crops by genotyping 12
Canadian-certified grain cultivars.
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FIGURE 2. Distribution of feral Cannabis sativa in Minnesota, United States and study sample locations. (A) Location of Minnesota in North America.
(B) Localities of Minnesota Department of Natural Resources observations and University of Minnesota herbarium (MIN) records from the Bell Museum.
(C) Three feral population localities sampled near the confluence of the Minnesota and Mississippi rivers. Precise locations are non-public data available upon request.

MATERIALS AND METHODS
Feral C. sativa

Minnesota feral plants were sampled in two successive years from
sites located along the riparian corridor near the confluence of the
Minnesota and Mississippi rivers (Fig. 2C). In 2015, we harvested all
aboveground biomass of 10 mature pistillate plants from each of two
locations. In 2016, we collected from the same two sites and a third
location by harvesting only the terminal 15 cm of the apical infructescence of 100 mature pistillate plants each. At one of the resampled
locations, three clandestinely planted individuals were encountered
but excluded from statistical analysis because they did not represent
the feral population. The total feral sample size was N = 317. Field
harvested plants and samples were dried in the laboratory for 3 weeks
at ambient conditions and separated into seed and floral fractions.
NIDA clinical C. sativa

Dried, unpollinated pistillate inflorescences representing 20 cultivars were obtained from the University of Mississippi production
facility with authorization from NIDA. Cannabinoid profiles of the
NIDA cultivars were not shared with the University of Minnesota
until after genotyping had been completed.
Canadian industrial C. sativa

Twelve industrial cultivars were grown from Canadian-certified
planting seed during June through September 2017 at the Minnesota
Agricultural Experiment Station (MAES) in Saint Paul, Minnesota.
Five mature, pistillate (or monecious) plants were sampled at 70
days after planting from each cultivar, and four additional samples
of each variety were collected at 105 days. Sampling of tissue at
MAES was conducted in the same manner as described above for
feral plants, yielding an industrial C. sativa sample of N = 108 with
nine samples per cultivar.

Cannabinoid profiling

Dried floral tissue samples were analyzed using gas chromatography (ElSohly et al., 2000) to measure the percentage of total inflorescence dry mass of seven compounds: cannabichromene (CBC),
CBD, cannabigerol (CBG), cannabinol (CBN), delta-8-tetrahydrocannabinol (d8-THC), THC, and tetrahydrocannabivarin (THCV).
We report percentage cannabinoid content as the sum of the individual compounds. Cannabinoid profiling was conducted on all
field-collected feral plants, a pistillate plant grown from feral seed in
the laboratory, six test-cross offspring of the feral parent, 20 NIDA
clinical cultivars, and 108 field-grown plants of industrial C. sativa.
CBDAS sequencing

We tested the inheritance model for the THC:CBD ratio by
genotyping functional (CF) and nonfunctional alleles (CX) of
CBDAS (Fig. 3A). Homozygous plants with CXCX and CFCF genotypes were predicted to have THC-type and CBD-type cannabinoid ratios, respectively, whereas heterozygous plants (CFCX)
were predicted to have an intermediate ratio. CBDAS genotypes
of 20 field-collected feral plants, two lab-reared feral offspring,
and six test-cross-derived plants were determined by Sanger
sequencing of ~960 bp following the method previously reported in our mapping study (Weiblen et al., 2015). PCR products were amplified with CBDAsynFor (ATG AAG TGC TCA
ACA TTC) and CBDA961Rev (CCA CTC CAC CAA GGA
AAA C) from gDNA isolated using a Plant DNeasy Kit (Qiagen,
Hilden, Germany). Briefly, products were sequenced from the
CBDAsynFor primer and aligned for comparison to reference
CBDAS sequence (GenBank accession KJ469374) using Geneious
10.2.5 (Biomatters, Ltd., Auckland, New Zealand).
CBDAS gel assay

Genotypes of 297 feral plants, 20 NIDA clinical cultivars, and
108 industrial C. sativa plants were determined using a cleaved
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FIGURE 3. Model of major chemotype inheritance corresponding to
CBDAS genotype. (A) Monohybrid inheritance in which mating between
heterozygous individual yields descendants that are homozygous for
functional CBDAS (CFCF), homozygous for nonfunctional CBDAS (CXCX),
or heterozygous (CFCX). The three classes have predominantly CBD, predominantly THC, or intermediate chemotypes. (B) Agarose gel CAPS
genotyping assay derived from presence or absence of a Bst1107I recognition site in functional (CF) and nonfunctional (CX) CBDAS alleles. In the
first lane is Invitrogen 1 Kb Plus DNA Ladder (Thermo Fisher Scientific,
Waltham, MA, USA). Lanes 2–4 are are verified genotypes from Weiblen
et al. (2015), and lanes 5–7 are feral individuals representing each of the
three genotypes. (C) Experimental verification of CBDAS inheritance by
crossing a CFCX female with a CXCX male sibling offspring from a CFCX feral
parent. Pedigree of (I) feral parents, (II) first generation offspring, and (III)
predicted second generation offspring. The genotype of the feral pollen
donor is uncertain (C?CX) but must have carried at least one non-functional allele (CX).

sequence-verified control samples (Fig. 3B). CBDAS CAPS genotyping of 56 test cross offspring was also performed on DNA isolated from hulled seeds using the REDExtract-N-Amp Seed PCR
Kit (Millipore Sigma, Burlington, MA, USA).
Feral offspring test cross

Using previously reported germination and growth protocols
(Weiblen et al., 2015), we reared offspring of a single feral intermediate-type plant known to be heterozygous (CFCX) for CBDAS
(Fig. 3C). Among the offspring, we crossed a heterozygous pistillate plant (CFCX) with a staminate plant that was homozygous
for nonfunctional CBDAS (CXCX). We collected mature seed
from the cross to compare the frequency of expected and observed allelic combinations in the F2 generation using a G-test
for goodness-of-fit.
Statistical analyses

amplified polymorphic sequence (CAPS) assay (Fig. 3B) that exploits a Bst1107I recognition site (GTATAC) present in functional
(CF) but absent in nonfunctional (CX) alleles of CBDAS. PCR products for the CAPS assay were obtained as described above. DNA
was isolated from floral tissue using a modified cetyl trimethylammonium bromide (CTAB) extraction buffer and organic extraction
(Doyle and Doyle, 1987), precipitated using sodium acetate and
ethanol, and digested with FastDigest Bst1107I (Thermo Fisher
Scientific, Waltham, MA, USA). Digested fragments were separated on 0.8% agarose/1X TAE gels. Genotypes were scored by
comparing digested fragment lengths of CBDAS PCR products to

Multiple comparison tests (Tukey HSD) of mean cannabinoid
content among feral, clinical, and industrial C. sativa plants,
and among CBDAS genotypes by THC:CBD ratio classes were
performed with the Least Squares function in JMP Pro 14.2.0
software (SAS, Cary, NC, USA). A likelihood ratio test for goodness-of-fit was calculated with the Distribution function in JMP
to detect departures from codominant Mendelian inheritance. A
likelihood ratio test for departure from Hardy–Weinberg equilibrium of observed feral CBDAS genotype frequencies was performed with ExactoHW 1.1 software (Engels, 2009). Cannabinoid
phenotypic data and CBDAS genotypes for individual plants are
provided in Appendix S1.
RESULTS
Feral cannabinoids

Among 317 pistillate, feral plants, we observed three distinct
THC:CBD ratio classes as measured by gas chromatography (Table 1;
Fig. 4A). Plants with a CBD-type ratio (THC:CBD ≤ 0.1) were
in greatest abundance at 88%, followed by intermediate-type
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TABLE 1. Cannabinoid ratio groups, CBDAS genotypes, and cannabinoid content of Minnesota feral, NIDA clinical, and Canadian certified industrial C. sativa.
Cannabinoid content, including total cannabinoid content (TCC) is reported as the mean percentage of inflorescence dry mass ± SE.
Minnesota feral
CBD-type
Intermediate
THC-type
NIDA clinical
CBD-type
Intermediate
THC-type
Industrial hemp
CBD-type
Intermediate

N

f

Genotype

%THC (SE)

%CBD (SE)

%TCC (SE)

280
33
4

0.88
0.11
0.01

CFCF
CFCX
CXCX

0.11 (0.00)
1.42 (0.11)
2.62 (0.48)

2.40 (0.08)
1.85 (0.15)
0.21 (0.06)

2.71 (0.09)
3.57 (0.28)
3.08 (0.53)

6
11
3

NA
NA
NA

CFCF
CFCX
CXCX

0.19 (0.01)
3.25 (0.28)
13.31 (0.27)

4.94 (0.27)
4.12 (0.26)
0.04 (0.00)

5.39 (0.30)
7.91 (0.55)
14.12 (0.29)

101
7

0.94
0.06

CFCF
CFCX

0.07 (0.00)
0.64 (0.07)

1.45 (0.09)
0.96 (0.11)

1.62 (0.10)
1.71 (0.19)

(THC:CBD ~1.0) at 11% and THC-type (THC:CBD ≥ 10.0) at 1%.
Numbers of intermediate and THC-type plants at each of three
sampling locations were 12, 20, 1, and 3, 1, 0, respectively. Total cannabinoid content per plant ranged from <1% to >10% and averaged
2.80% ± 0.09 SE (Fig. 4C). The distribution was skewed in favor
of most plants (62%) having less than 3% total cannabinoid content.

were heterozygous (CFCX), and all four THC-type plants were homozygous for nonfunctional CBDAS (CXCX). Allele frequencies
among feral plants for functional and nonfunctional variants were
CF = 0.94 and CX = 0.06, respectively. The observed frequency of the
CXCX genotype (four plants) slightly exceeded the Hardy–Weinberg
expectation (exact test, P = 0.0318).

Feral CBDAS

Feral test cross

CBDAS genotypes of feral plants (Table 1) matched the predictions
of the model (Fig. 3A). All 280 CBD-type plants were homozygous for functional CBDAS (CFCF), all 33 intermediate-type plants

The test cross between a heterozygous, pistillate plant (CFCX)
and a staminate plant homozygous for nonfunctional CBDAS
(CXCX) was consistent with the inheritance of CBDAS genotypes

FIGURE 4. Cannabinoid profiles of Minnesota feral and industrial C. sativa sampled across 12 field-grown Canadian certified grain and dual use cultivars.
(A) Percentage dry mass THC versus CBD among 317 Minnesota feral plants. The horizontal dashed line marks the 0.3% THC statutory threshold, and
the solid line indicates a 1:1 THC:CBD ratio. Symbols for CBDAS genotypes are + (CXCX), ▲ (CFCX), and ● (CFCF). (B) Percentage dry mass THC versus CBD
among 108 industrial hemp plants representing 12 Canadian-certified grain cultivars (9 samples/variety) grown in Saint Paul, Minnesota. (C) Distribution
of total cannabinoid content among 317 Minnesota feral plants. (D) Distribution of total cannabinoid content among the 108 industrial hemp plants.
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according to a single-locus Mendelian factor. Genotyping of 62
offspring of the test cross yielded nearly equal proportions of
the two predicted genotypes and a few individuals of an unexpected third genotype (29 CXCX, 30 CFCX, and 3 CFCF). Genotype
frequencies were not significantly different from expectations
(G = 0.017; P = 0.90; Fig. 3C). The three offspring homozygous
for functional CBDAS could have resulted from self-pollination
given the occurrence of occasional, adventitious staminate flowers in pistillate inflorescences. Male sex expression is commonly
observed at low frequency in genetically female C. sativa plants
(Hirata, 1927).
NIDA C. sativa

Blind genetic testing of 20 NIDA clinical cultivars yielded all three
CBDAS genotypes (Table 1). Total cannabinoid content in the clinical samples ranged from 4.5% to 14.7% (mean = 8.1% ± 0.7 SE)
and was significantly greater on average than Minnesota feral C.
sativa (Tukey HSD: t = −15.08, df = 442; p < 0.0001). Regardless of
total cannabinoid content, the THC:CBD ratios revealed after genotyping perfectly matched model predictions based on the observed
CBDAS genotypes (Table 1).
Industrial C. sativa

Among 108 field-grown plants representing 12 Canadiancertified grain cultivars (including four dual use, grain/fiber
cultivars), 101 individuals were homozygous for functional
CBDAS (CFCF), and seven were heterozygous (CFCX). Each of
the seven heterozygotes had an intermediate THC:CBD ratio and exceeded the <0.3% THC statutory threshold (Table
1; Fig. 4B). A subset of the homozygous plants (20 of 101) had
intermediate THC:CBD ratios but had significantly lower total cannabinoid content (mean = 0.40% ± 0.04 SE) than either
heterozygous intermediates (mean = 1.71% ± 0.19 SE; Tukey
HSD: t = 3.62, df = 105, P = 0.0013) or homozygous CBD-type
plants (mean = 1.93% ± 0.10 SE; Tukey HSD: t = 7.42, df = 105,
P < 0.0001). Compared to feral C. sativa, Canadian-certified
cultivars collectively had significantly lower cannabinoid content (mean = 1.63% ± 0.10 SE; Tukey HSD: t = 6.93, df = 442,
P < 0.0001) and a similarly skewed distribution but with a far
greater proportion of plants (90%) containing less than 3.0% total cannabinoid content (Fig. 4D).
DISCUSSION
Cannabinoids

It is not widely known that the discovery of CBD can be traced
to Minnesota where it was first isolated from fiber-type C. sativa
(Adams et al., 1940). Loss of access to Philippine fiber during
World War II prompted the Defense Plant Corporation, a U. S.
federal agency, to temporarily license and subsidize C. sativa cultivation in Minnesota (Dewey, 1943). Escape and naturalization
resulted in widespread populations of feral C. sativa throughout
the upper Midwest (Nugent, 1938; Schoenrock, 1966). We used
Minnesota feral C. sativa to validate a predictive model for the
inheritance of the THC:CBD ratio. Genotyping of clinical and industrial C. sativa suggests a general association between allelic

variation at the CBDAS locus and the three main classes of the
THC:CBD ratio.
CBDAS in feral C. sativa

The complete correspondence of THC:CBD ratio classes with
CBDAS genotypes in Minnesota feral C. sativa provides strong evidence for the generality of the model of inheritance that was derived from inbred biparental genetic mapping (Fig. 3A) (Weiblen
et al., 2015). Also supporting generality were sequences from 20
feral, THC-type or intermediate plants sharing the same diagnostic
four-base frameshift deletion previously reported for nonfunctional
CBDAS isolated from THC-type C. sativa (Weiblen et al., 2015).
Using the CAPS assay based on this diagnostic deletion, an additional 297 feral plants also associated CBDAS genotypes with the
three THC:CBD ratio groups. The marginally significant departure
of CBDAS genotype frequencies from Hardy–Weinberg equilibrium might represent a Type I statistical error given only four THCtype plants among 317 individuals. Additional study is needed to
evaluate the potential for non-equilibrium processes to have shaped
feral CBDAS genotype frequencies, including the possibility of phenotypic selection for cannabinoids as deterrents to seed predation
(Small, 2016).
Identifying THC-type plants among first generation offspring of
a feral intermediate plant signaled the presence of pollen donors
harboring THC-type alleles as would be expected in a segregating
field population. Experimental crossing of offspring from a feral intermediate produced 59 of 62 genotypes that were consistent with
the expected segregation of CBDAS genotypes in the subsequent
generation.
Unexplained cannabinoid variation

Despite evidence from feral C. sativa for incomplete dominance affecting the THC:CBD ratio, variance within each of the three ratio
classes remains unexplained and deserves further study. Similar to
the segregating population of Weiblen et al. (2015), variation was
greatest among the feral intermediate class (Fig. 4A), and intermediate-type plants had slightly higher quantities of CBD than THC.
Considering that these two cannabinoids share a common precursor (CBG), we speculate that CBDAS is a superior competitor to
THCAS either in terms of substrate affinity or catalytic efficiency.
Industrial C. sativa had the same pattern (Fig. 4B), although with
less variation within classes than feral C. sativa, as would be expected for a domestic crop variety.
Another major component of cannabinoid variation not explained by the THC:CBD ratio model is the nearly 10-fold range
in total cannabinoid content (Fig. 4C, D). A broad range of variation was observed in all three ratio classes (Fig. 4A, B), indicating
that the inheritance of cannabinoid quantity is independent of the
THC:CBD ratio. Quantitative trait locus (QTL) analysis identified
QTL for total cannabinoid content on five different chromosomes
(Grassa et al., 2018 [Preprint]), and none were linked to the single QTL that is strongly associated with the THC:CBD ratio or the
genes for CBDAS and THCAS on chromosome 7 (Fig. 5A). Whether
any of the independent QTLs are associated with differential gene
regulation affecting CBD or THC production is an intriguing question for future study. Alternatively, it has been hypothesized that
cannabinoid gene copy number influences potency (Kovalchuk
et al., 2020).
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developing foundation seed or multiplying certified seed could be confounded
by pollen drift from nearby feral or cultivated C. sativa harboring THC-type
alleles (Small and Antle, 2003). Stokes
et al. (2000) reported up to 36% C. sativa
pollen during August in airborne pollen
samples from the midwestern United
States. Aerodynamic models of pollen
dispersal could be tested in the field to
evaluate whether the recommended
isolation distance of 5 km is sufficient
to maintain the genetic purity of a C. sativa crop. Regardless, the contractual obligation to neither plant nor multiply seed
saved from a certified crop is especially
important given the potential for pollen
contamination to increase the frequency
of plants with >0.3% THC in subsequent
generations.
There are several situations in which
the CBDAS genotype assay might have
practical value. Many populations of C.
sativa classified as "hemp" are segregating
for THC-type alleles (Toth et al., 2020).
The risk of THC-type alleles contaminating certified fiber and grain cultivars
could be minimized by screening seed
lots at all stages of breeding and mulFIGURE 5. (A) Alignment of a chromosome 7 physical map for C. sativa (Grassa et al., 2018) with the
tiplication to assure purity. When seed
corresponding linkage group from the segregating F2 population of Weiblen et al. (2015). A single
provenance is uncertain or questionable,
QTL at 38.9 cM, accounting for >90% of variance in the THC:CBD ratio, maps to a region between 20.6
genetic testing of samples prior to plantMb and 31.5 Mb on chromosome 7. Genes for THCAS and CBDAS are located within this region at 26
ing could reduce the risk of non-comMb and 31 Mb, respectively. (B) Model in which THC-type and CBD-type plants are reciprocally homopliant crops. Farming “industrial hemp”
zygous for alternately functional (f ) and nonfunctional (x) alleles of THCAS and CBDAS. Intermediateis a risky proposition at present because
type plants are heterozygous at both loci. (C) Punnett square for selfing the F1 intermediate of a
crops are tested near maturity for THC
hybrid cross. According to the close linkage of the loci, we predict that recombinants are not likely to
regulatory compliance.
be observed among the F2 descendants of hybrid crosses.
The homozygous functional CBDAS
genotype accurately identified all 101
industrial C. sativa plants that were compliant with the <0.3%
Assaying clinical and industrial C. sativa
THC statutory definition of industrial hemp. However, 20 plants
We extended the utility of the CBDAS assay by blindly genoamong the compliant individuals had exceptionally low total cantyping 20 clinical cultivars obtained from the NIDA production
nabinoid content (<0.5%). When cannabinoids were this scarce, the
facility in Mississippi. Only after genotyping were the cannabiTHC:CBD ratio was closer to intermediate type than to either the
noid profiles from Mississippi shared with the investigators in
THC-type or CBD-type. Uncertainty associated with sample prepaMinnesota. CBDAS genotypes predicted the three THC:CBD raration or gas chromatography in the range of ±0.1–0.3% might have
tio classes with 100% accuracy, suggesting that CBDAS genotypes
skewed the THC:CBD ratio and obscured the distinction between
can generally predict THC:CBD ratios in drug cultivars. Applying
the intermediate and CBD-type. Alternatively, novel genetic mechthe assay to a set of 108 samples from 12 Canadian-certified inanisms might await discovery. In any event, the homozygous funcdustrial cultivars (grain and dual-use) also suggest broad diagtional CBDAS genotype correctly predicted that even these 20
nostic utility.
plants were compliant with the <0.3% THC statutory definition of
We were surprised to discover that 6% of plants grown from
industrial C. sativa.
Canadian-certified seed exceeded the <0.3% THC statutory definition of industrial C. sativa. All seven plants had an intermediate
THC:CBD ratio inheritance model
THC:CBD ratio and the expected heterozygous CBDAS genotype.
Had THC testing been performed on homogenized samples taken
The CBDAS genotype accurately predicted all three THC:CBD
from multiple plants or if the results of several independent tests
ratio classes in diverse C. sativa gene pools, supporting its broad
were averaged for a given population, the low frequency of nonutility. The simplest genetic explanation for this association would
compliant plants could have escaped detection during the multiplibe if CBDAS and THCAS represent alternate alleles of a single location of certified seed. Even the most stringent THC testing when
cus (de Meijer et al., 2003). However, there are at least two or more
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tightly linked cannabinoid synthase loci in diverse accessions of
C. sativa (van Bakel et al., 2011; Onofri et al., 2015; Weiblen et al.,
2015; Grassa et al., 2018 [Preprint]; Laverty et al., 2019). Recent
annotation of several C. sativa genome assemblies (Grassa et al.,
2018 [Preprint]; Laverty et al., 2019), including one anchored with
whole-genome shotgun sequencing of an F2 mapping population
(Weiblen et al., 2015), indicate that separate loci for THCAS and
CBDAS are tightly linked in a chromosomal region of highly suppressed recombination. Grassa et al. (2018; Preprint) proposed the
physical arrangement of the synthases in close proximity on chromosome 7 (Fig. 5A). Based on these findings, we suggest a mechanistic model explaining the predictive power of the CBDAS
genotype with respect to THC:CBD inheritance. In CBD-type
plants, the expressed CBDAS is tightly linked to a nonfunctional
and/or under-expressed THCAS. In THC-type plants, a nonfunctional and underexpressed CBDAS is tightly linked to a functional
and overexpressed THCAS. Tight genetic linkage of the synthases
renders CBD-type and THC-type plants reciprocally homozygous
for the respective alleles, whereas intermediate plants are reciprocally heterozygous (Fig. 5C).
The conserved four-base deletion at position 153 in the CBDAS
sequence that renders it nonfunctional (Weiblen et al., 2015) and
is the target of the CAPS assay appears to exist in THC-type and
intermediate plants among diverse C. sativa accessions (Table 2).
Although the model of incomplete dominance for the THC:CBD
ratio seems robust, it does not completely account for cannabinoid inheritance. In particular, the potential influence of gene copy
number on cannabinoid expression deserves further consideration
(Kovalchuk et al., 2020).

CBDAS versus THCAS

When the first CBDAS sequence was published Taura et al. (2007)
reported additional homologs in fiber-type C. sativa. Subsequent
studies have suggested that cannabinoid synthase and synthase-like
sequences are likely duplicated (Onofri et al., 2015; Weiblen et al.,
2015). BLAST searches with the original CBDAS sequence return
no fewer than 37 hits described as CBDAS compared to 94 hits
described as THCAS with the first reported THCAS sequence
(Sirikantaramas et al., 2004). The CBDA961Rev primer reported
here amplifies CBDAS (CF) and nonfunctional CBDAS (CX) to the
exclusion of potentially confounding cannabinoid synthase gene
copies (Table 2). The association of functional and nonfunctional
CBDAS alleles with THC-type plants and intermediate plants has
also been independently affirmed in a broader survey of European
C. sativa (Cascini, 2019) and in feral New York populations (Toth
et al., 2020). Functional CBDAS is present in the genome of the
CBD-type cultivar Finola but absent from the THC-type Purple
Kush (Laverty et al., 2019). As predicted by the model, a CBDAS
sequence bearing the four-base (CX) deletion is found in the Purple
Kush genome assembly but not in Finola.
We suggest that CBDAS genotype assays may be more informative than existing THCAS polymorphisms because the latter
alone do not yet distinguish THC-type plants from intermediates
(Rotherham and Harbison, 2011; Staginnus et al., 2014). One explanation for the limited diagnostic power of THCAS-based assays
is that a conserved and presumably nonfunctional allele of THCAS
has not been identified. Cannabinoid synthase sequences from both
drug and fiber cultivars previously thought to be copies of THCAS

TABLE 2. Cannabinoid synthase sequence alignment including the four-base deletion that distinguishes functional (CF) from nonfunctional (CX) alleles of cannabidiolic
acid synthase (CBDAS). A Bst1107I restriction site spans the deletion. Downstream sequences from 943 to 961 bp illustrate how the reverse primer CBDA961Rev
selectively amplifies CBDAS over other cannabinoid synthases. Gene sequences are annotated as CBDAS, CBDAS-like, THCAS, or CBCAS according to Grassa et al. (2018)
for cultivars including Carmen hemp (Weiblen et al., 2015), CBDRx (Grassa et al., 2018), drug type (Sirikantaramas et al., 2004), fiber type (Taura et al., 2007), Finola
(Laverty et al., 2019), Purple Kush (Laverty et al., 2019), and Skunk #1 (Weiblen et al., 2015).
Sequence position (bp)
Gene

Cultivar

Accession

Bst1107I

CBDAS (C F )

Carmen

KJ469374

AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG

CBDAS (C F )

142

153

CBDA961 reverse complement
170...943

961

fiber type

AB292682

AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG

F

Finola

CM011610

AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG

F

CBDAS (C )

CBDRx

LR213635

AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG

CBDAS (C X )

Skunk #1

KJ469375

AATCTAAAACT----TACACCCAAAACAA…….GTTTTCCTTGGTGGAGTGG

CBDAS (C X )

Skunk #1

KJ469376

AATCTAAAACT----TACACCCAAAACAA…….GTTTTCCTTGGTGGAGTGG

CBDAS (C )

X

CBDAS (C )

Purple Kush

CM010792

AATCTAAAACT----TACACCCAAAACAA…….GTTTTCCTTGGTGGAGTGG

CBDAS-like

fiber type

AB292683

AATGCAAAACTCGTATACACTCAACACGA……ATTTTCCATGGTGGAGTGG

CBDAS-like

CBDRx

LR213635

AATGCAAAACTCGTATACACTCAACACGA……ATTTTCCATGGTGGAGTGG

THCAS

Skunk#1

KJ469378

AATCCAAAACTCGTATACACTCAACACGA……ATTTTTCATGGTGGAGTGG

THCAS

drug type

AB057805

AATCCAAAACTCGTATACACTCAACACGA……ATTTTTCATGGTGGAGTGG

CBCAS

Purple Kush

JH227480

AATCCAAAATTCATATACACTCAACACGA……ATTTTTCTTGGTGGAGTGG

CBCAS

Carmen

KJ469380

AATCCAAAATTCATATACACTCAACACGA……ATTTTTCTTGGTGGAGTGG

CBCAS

Skunk #1

KJ469379

AATCCAAAATTCATATACACTCAACACGA……ATTTTTCTTGGTGGAGTGG
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(Kojoma et al., 2006; Weiblen et al., 2015) turned out to be cannabichromenic acid synthase (CBCAS) according to Laverty et al. (2019).
Adding to the confusion, sequences from CBD-type plants annotated by Rotherham and Harbison (2011) as THCAS are more similar to CBCAS (Grassa et al., 2018 [Preprint]; Laverty et al., 2019).
It is possible that the high sequence similarity of different synthase
genes and subsequent misidentification have confounded efforts to
develop diagnostic assays of the THC:CBD ratio based on THCAS
polymorphisms. Perhaps it is the highly suppressed recombination
in the physical region harboring reciprocally linked, functional and
nonfunctional alleles that maintains the single locus-like pattern of
cosegregation. This hypothesis predicts the existence of a nonfunctional THCAS allele that might yield a THCAS-based codominant
assay similar to the CBDAS-based assay (Fig. 5C).
Feral problems and prospects

Due to research restrictions resulting from the Controlled
Substances Act of 1970, few data on the cannabinoid profiles or
genetics of feral C. sativa were available until recently (Datwyler
and Weiblen, 2006). The rarity of THC-type plants in feral populations and the odds of locating one-in-a-hundred are consistent
with the popular opinion that “ditch weed” is non-intoxicating.
Our findings are at the same time consistent with law enforcement concerns about feral populations concealing drug-type C.
sativa, although their low frequency undercuts the efficiency of
drug eradication. We would like to know whether the presence of
THC-type and intermediate-type plants in feral populations is due
to the impurity of historical fiber cultivars or to more recent introgression of THC-type genetics from clandestine drug operations.
Two arguments favor historical impurity. First, THC and CBD
were not characterized chemically until long after the introduction
of fiber hemp to Minnesota such that neither breeders nor producers of hemp could accurately assess purity. Second, THC-type pollen
is unlikely to be abundant in the landscape relative to feral pollen
based on horticultural practice for drug production. Unpollinated
inflorescences are known to invest resources in excessive trichome
formation and cannabinoid production (Merlin and Clark, 2013).
Drug operations either cultivate clonally propagated pistillate plants
(females) or remove staminate plants (males) to avoid pollination
and increase the potency of the crop.
Alternatively, the nonfunctional CBDAS allele might have been
introduced to feral populations by dispersal of THC-type pollen from
cultivation and escape of drug-type C. sativa. Pollen can travel distances up to kilometers in wind-pollinated species such as C. sativa,
and long-distance seed dispersal by birds has even greater potential
to influence the migration of genes among populations (Small, 2016).
Additional work is needed to examine population genetic patterns
and processes by sampling feral C. sativa geographically and by comparing locations with different histories of fiber and drug cultivation.
Feral populations could be a valuable source of germplasm for
breeding and provide opportunities to investigate the inheritance
of quantitative variation in total cannabinoid content (potency).
Genetic mechanisms influencing cannabinoid quantity are currently a subject of untested speculation. None of the QTL for potency that have been identified are linked to THCAS or CBDAS but
are rather associated with different chromosomes (Weiblen et al.,
2015; Grassa et al., 2018 [Preprint]). Breeding to increase the yield
of CBD while maintaining THC levels below the legal limit is an
obvious potential application, as is breeding for fiber and grain
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yield. At least 70 generations of feral adaptation to regional soil and
climate conditions present both opportunities and challenges for
re-domestication.
Broader implications

The presence of more than one of the three cannabinoid classes in
feral, industrial, and clinical populations renders the dichotomy between “hemp” and “marijuana” meaningless from a botanical perspective. Other classes of plants add to the complexity of C. sativa. For
example, Fournier (2004) reported cultivars producing mostly CBG,
the common precursor to THC and CBD. We avoided using common
names not simply because they misrepresent patterns in nature and
fail to match statutory intent. The dichotomy between “hemp” and
“marijuana” perpetuates culturally biased and pejorative assumptions
about C. sativa that have hindered scientific investigation for nearly a
century (Abel, 1980). Rooted in colonial history, North American C.
sativa has literally and figuratively escaped from that past, adapting
and thriving today across a diverse array of natural ecosystems and
engineered systems. A decolonized definition recognizing THC-type,
CBD-type, intermediate-type, and CBG-type plants would be more
accurate botanically and perhaps more practical as the use and regulation of C. sativa continues to expand and diversify.
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